Doprava zdarma pre objednávky nad 59,99 € s Packetou a SPS Boxmi.

Zistiť stav objednávky

Staňte sa súčasťou komunity milovníkov kníh z celého sveta a získajte hromadu výhod. Založiť účet zdarma

Doprava zadarmo s Packetou nad 59.99 €

Kuriér DPD 2.99 € Zberné miesto GLS 2.49 € SPS 3.99 € SPS Parcel Shop 2.99 € Packeta kurýr 3.99 € Slovenská pošta 3.99 € Zberné miesto DPD 2.99 € Kuriér GLS 3.99 € Packeta 2.99 €

Kontakt

Ako nakupovať

Pomoc

Môj účet

▸ Prázdny :-(

Doprava zdarma pre objednávky nad 59,99 € s Packetou a SPS Boxmi.

Activity-based proteomics

Name: Activity-based proteomics
Brand: Sudwestdeutscher Verlag Fur Hochschulschriften AG
SKU: 07148241
Price: 47.98 EUR
Availability: InStock
Author: Thomas Wiedl
ISBN: 9783838131375

Thomas Wiedl

Jazyk

Angličtina

Kniha Brožovaná

Libristo kód: 07148241

Nakladateľstvo Sudwestdeutscher Verlag Fur Hochschulschriften AG, február 2012

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ra... Celý popis

Libristo kód: 07148241

116 b

47.98 €

Skladom u dodávateľa Odosielame za 8-11 dní

Až 30 dní na vrátenie tovaru

Zákazníci tiež kúpili

Oscar Wilde's "Dorian Gray" in drei deutschen Übersetzungen Corinna Clauß

Brožovaná

49.90 €

Zulassigkeit der Nothwehr gegenuber beleidigenden AEusserungen, Leopold Bauke

Brožovaná

11.71 €

Šumava krásná a tajemná Martin Čihař

Pevná

12.11 €

Legislacion de marcas, patentes y diseño industrial RICARDO ALONSO

Pevná

67.38 €

Fosilie Michal Kašpárek

Brožovaná

11.10 €

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ranges from 80% in early stages to less than 5% in advanced disease. Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung malignancies, 40% of which are adenocarcinomas representing one of the most common lung cancer subtypes. Currently, prognosis is mostly determined based on the extension of disease at diagnosis. Thereby it has become evident that predicted and real outcomes can vary significantly, even for patients with the same stage of disease. Thus, novel biomarkers that refine prognosis with a reliable clinical significance are clearly needed. Therefore we aimed to implement an activity-based proteomics platform representing a powerful tool in the search for novel disease biomarkers.